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Abstract
Background: The existence of cancer stem cells (CSCs) or cancer stem-like cells in a tumor mass is believed to be
responsible for tumor recurrence because of their intrinsic and extrinsic drug-resistance characteristics. Therefore, targeted
killing of CSCs would be a newer strategy for the prevention of tumor recurrence and/or treatment by overcoming drug-
resistance. We have developed a novel synthetic compound-CDF, which showed greater bioavailability in animal tissues
such as pancreas, and also induced cell growth inhibition and apoptosis, which was mediated by inactivation of NF-kB,
COX-2, and VEGF in pancreatic cancer (PC) cells.
Methodology/Principal Findings: In the current study we showed, for the first time, that CDF could significantly inhibit the
sphere-forming ability (pancreatospheres) of PC cells consistent with increased disintegration of pancreatospheres, which
was associated with attenuation of CSC markers (CD44 and EpCAM), especially in gemcitabine-resistant (MIAPaCa-2) PC cells
containing high proportion of CSCs consistent with increased miR-21 and decreased miR-200. In a xenograft mouse model
of human PC, CDF treatment significantly inhibited tumor growth, which was associated with decreased NF-kB DNA binding
activity, COX-2, and miR-21 expression, and increased PTEN and miR-200 expression in tumor remnants.
Conclusions/Significance: These results strongly suggest that the anti-tumor activity of CDF is associated with inhibition of
CSC function via down-regulation of CSC-associated signaling pathways. Therefore, CDF could be useful for the prevention
of tumor recurrence and/or treatment of PC with better treatment outcome in the future.
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Introduction
Pancreatic cancer (PC) is one of the most lethal malignant
diseases with worst prognosis, which is ranked as the fourth leading
cause of cancer-related deaths in the United States [1]. Over the
past two decades, numerous efforts have been made in improving
treatment and survival PC patients but the outcome has been
disappointing. This disappointing outcome is due to many factors
among which de novo resistance (intrinsic) and acquired (extrinsic)
resistance to conventional therapeutics (chemotherapy and
radiation therapy) including gemcitabine alone or in-combination
with other cytotoxic or targeted agents. Emerging evidence suggest
that the resistance could in fact be due to the enriched existence of
tumor initiating cells, also classified as cancer stem-like cells (CSC)
in a tumor mass [2–6]. The CSCs have the capacity of self-renewal
and the potential to regenerate into all types of differentiated cells
giving rise to heterogeneous tumor cell populations in a tumor
mass, which contributes to tumor aggressiveness [2–6]. Thus, the
failure to eliminate these special cells is considered to be one of the
underlying causes of poor treatment outcome with conventional
therapeutics, suggesting that newer and novel therapeutic
strategies must be developed for the targeted killing of drug
resistant CSCs in order to eradicate the risk of tumor recurrence
for improving the survival of patients diagnosed with PC.
In search of novel yet non-toxic agents, attention has been
focused on natural agents for several years. One such agent is
curcumin (diferuloylmethane), which is derived from the plant
Curcuma longa (Linn) grown in tropical Southeast Asia [7–9].
Curcumin has been shown to inhibit the growth of a variety of
tumor cells; however, the poor bioavailability of curcumin limits its
application in the clinic. Recently, we have developed a novel
synthetic analogue of curcumin, 3,4-difluoro-benzo-curcumin [we
named it as Difluorinated-Curcumin or in short CDF [10,11]],
which showed greater bioavailability in pancreatic tissues, and also
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2, and the production of PGE2 and VEGF, and caused induction
of miR-200 and inactivation of miR-21 in PC cells [12]. Since
miR-200 is associated with the acquisition of epithelial to
mesenchymal transition (EMT), which is also believed to be
associated with CSCs or cancer stem-like cells, here we
investigated the effects of CDF on CSC function.
Here we report, for the first time, that CDF could inactivate
many functions of CSCs including self-renewal capacity as
demonstrated by the inhibition of sphere-forming (pancreato-
spheres) ability of drug-resistant PC cells, which was consistent
with inactivation of CSC biomarkers such as CD44 and EpCAM.
We also showed anti-tumor activity of CDF alone and in-
combination with gemcitabine, which was consistent with
inactivation of miR-21, and consequently increased expression of
PTEN, attenuation of the DNA binding activity of NF-kB
inhibition in the expression of COX-2, and activation in the
expression of miR-200 in tumor remnants of a xenograft mouse
model of human PC, all of which provide convincing in vivo activity
of CDF which is consistent with in vitro findings.
Results
AsPc-1and MIAPaCa-2 celllines and their cloneswerechosenfor
this study because of their relatively resistant nature. The CSC
characteristics of these cell lines using stem cell markers’ Lin28B and
Nanog by RT-PCR, and EpCAM and CD44 by western blot
showed an increase in expression level in the PC-GTR cell lines
compared totheirparental celllines (Figure 1).Hence we chosethese
to test our hypothesis that CDF is more effective than curcumin even
in resistant cell lines and also their resistant clones–GTR.
CDF strongly prevents clonogenicity and invasion of PC
cells compared to gemcitabine and curcumin
We selected the concentration of 20 nmol/L of gemcitabine and
4 mmol/L of curcumin or CDF to conduct clonogenic assay
following our previous publication [12]. The results demonstrated
that there was a significant reduction in clonogenicity of AsPC-1
and MIAPaCa-2 cells treated with curcumin and CDF, but not
with gemcitabine (Figure 2A). However, CDF treatment had a
much greater and significant reduction in colony formation
compared to curcumin. AsPC-1-GTR and MIAPaCa-2-GTR
cells had an 80% reduction of clonogenicity with CDF treatment,
whereas, only 20–30% reduction of clonogenicity was observed
with gemcitabine or curcumin treatment (Figure 2A). Overall,
CDF treatment showed a significant reduction in clonogenicity of
human PC cells, suggesting the superiority of CDF.
CDF or curcumin treatment decreased PC cell migration and
invasion. The results showed that 4 mmol/L of curcumin had
minimal inhibition of invasion whereas similar concentration of
CDF showed significant inhibition of invasion (Figure 2B). The
basal level of ABCG2 expression was found in parental cell lines (de
novo drug resistant cells); however, the level of expression of
ABCG2 was further increased in drug resistant (acquired drug
resistant) cell lines (Figure 2C).
CDF inhibited viability of human PC cells more than
curcumin and gemcitabine as evaluated by MTT assay
Initially MTT assay was conducted to examine the effect of
different concentrations of gemcitabine (1 to 50 nmol/L), and
curcumin or CDF (2–6 mmol/L) on cell survival after 72h of
treatment (data not shown). Subsequently, 4 mmol/L of CDF or
Figure 1. Comparative expression of Lin28B (A) and Nanog (B) mRNA by qRT-PCR showed increased expression in resistant cell
lines compared to parental cell lines, supporting the CSC characteristics of these cell lines. The characteristics of CSCs were further
confirmed by the protein expression of EpCAM and CD44 (C).
doi:10.1371/journal.pone.0017850.g001
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individually as well as in combination with gemcitabine for 72h.
The results showed that CDF treatment in combination with
gemcitabine caused a remarkable reduction of cell survival in all
four cell lines compared to curcumin and gemcitabine combination
treatment (Figure 3). Furthermore, analysis of drug combination
treatment showed that the combination index after treatment with
CDF in combination with gemcitabine was less than 1.00 (Figure 3),
suggesting the synergistic effect of CDF combination. In contrast, the
combination index with curcumin and gemcitabine was more than
1.00 (Figure 3), showing non-synergistic effect. Overall, these results
suggest that CDF caused a much more significant reduction of cell
survival in PC cells, compared to gemcitabine/curcumin alone or
their combinations compared to CDF and gemcitabine combination.
Figure 2. CDF and Curcumin decreased clonogenicity and invasion in AsPC-1, AsPC1-GTR, MIAPaCa-2, and MIAPaCa-2-GTR cells.
Clonogenic assay (A) Invasion assay (B). Fluorescence of the invaded cells was read using ULTRA Multifunctional microplate reader (TECAN) at
excitation/emission wavelengths of 530/590 nm. Basal level of ABCG2 expression showing relatively higher expression in drug resistant cell lines (C).
doi:10.1371/journal.pone.0017850.g002
Figure 3. CDF and its combination with gemcitabine inhibited cell viability. MTT assay was conducted in all four cell lines after 72h of
treatment with CDF, curcumin, or its combination with gemcitabine. Untreated control has been assigned a value of 100%. The p value shown
represents comparisons between single agent and their combinations by using paired t-test. The combination Index (CI) ,1 for CDF and Gemcitabine
combination indicates synergism.
doi:10.1371/journal.pone.0017850.g003
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disintegration of PC cells
To examine the effect of treatments on the sphere forming ability
of PC cells (pancreatosphere) and disintegration of pancreato-
spheres, we conducted sphere disintegration assay for 10 days to
generate the formation of pancreatospheres, followed by 5 days of
drug treatment. The results show that there was a remarkable
increase of sphere disintegration by curcumin and CDF treatment,
not by gemcitabine treatment (Figure 4). However, the greatest
effect on disintegration was observed in response to the CDF
treatment (Figure 4), once again suggesting that CDF is much more
superior in inhibiting the functions of cancer stem-like cells.
CDF inhibited pancreatospheres formation in PC cells
To examine the effect of drugs on CSC self-renewal capacity in PC
cells, we conducted sphere formation assay for 1 week and four weeks
(Figure 5A and B). The results indicated that CDF in combination
with gemcitabine completely eliminated pancreatospheres formation
after four weeks of treatment compared to gemcitabine and curcumin
combination in PC cells even in gemcitabine-resistant PC cells,
suggesting that CDF may cause the pancreatospheres more sensitive
to gemcitabine than that of curcumin treatment, and could be useful
for targeted killing of CSCs. Figure 5C shows the effect of different
concentration of gemcitabine and CDF on 2
nd passage of pancreato-
spheres in pre-treated primary pancreatospheres of AsPC-1 cells.
CDF treatment remarkably inhibited 2
nd passage of pancreato-
spheres in a dose-dependent manner. Furthermore, CDF-pre-treated
cells exhibited a greater effect than non-CDF-pre-treated cells.
CDF decreased CD44 and EpCAM expression in
pancreatospheres of PC cells
We examined the effect of drugs on CSC biomarkers, CD44
and EpCAM in pancreatospheres of AsPC-1 and AsPC-1-GTR
cells by confocal microscopy (Figure 6). The results indicate that
CDF decreased CD44 and EpCAM expression in pancreato-
spheres, suggesting the inhibitory effect of CDF on pancreato-
Figure 4. CDF remarkably increased disintegration of pancreatospheres in AsPC-1, AsPC1-GTR, MIAPaCa-2, and MIAPaCa-2-GTR
cells. P values were calculated by the paired t test.
doi:10.1371/journal.pone.0017850.g004
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treatment (B); AsPC-1 and CDF-pre-treated AsPC-1 cells treated with gemcitabine and CDF (C). A significant reduction in
pancreatospheres was observed in cells treated with CDF shown by asterisk.
doi:10.1371/journal.pone.0017850.g005
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and EpCAM expression.
CDF in combination with Gemcitabine inhibited
Pancreatic Tumor Growth in vivo much more than
curcumin combination
We have used a subcutaneous xenograft tumor model where the
tumor was induced by MIAPaCa-2 cells in CB17-SCID mice.
CDF treatment in combination with gemcitabine significantly
inhibited tumor growth in MIAPaCa-2 tumors much more than
curcumin and gemcitabine combination (Figure 7A) as well as
compared to either untreated controls or those treated with a
single drug. The mice did not show any weight loss during the
treatment period (30 days), suggesting that these treatment had no
major adverse effects on animals.
CDF with Gemcitabine significantly decreased NF-kB
Activation in vivo
NF-kB activation was determined in the CDF or curcumin,
and/or gemcitabine treated tumor remnants derived from
MIAPaCa-2 cells induced tumors as shown above. CDF and
curcumin as single agent down-regulated NF-kB activation
whereas gemcitabine activated NF-kB level, which was abrogated
in combination treatment with CDF. The combination treatment
of CDF with gemcitabine showed a significant decrease in NF-kB
level compared to curcumin and gemcitabine treatment (Figure
7B), suggesting that the inactivation of NF-kB could be one of the
molecular mechanisms by which CDF elicits its anti-tumor activity
against PC tumors.
CDF effects on protein expression in vivo
The COX-2, PTEN, and b-actin expression was determined by
Western blot. A significant down-regulation in the expression of
COX-2 was observed in both the combination, but the effect was
more pronounced in CDF combination group. The expression of
phosphatase and tension homolog (PTEN), a tumor suppressor
gene was found to be decreased in MIAPaCa-2 cells; however, the
expression of PTEN was up-regulated when treated with CDF
(Figure 7C). These results suggest that CDF is much more effective
than curcumin. Since PTEN is a known target of miR-21, which
has been reported to be up-regulated in PC [13–15], we assessed
the expression levels of miR-21 in tumor remnants as shown
below.
Modulation in the expression of miR-21 and miR-200
family in vivo
We determined the expression levels of miR-21, miR-200b and
miR-200c in MIAPaCa-2 tumors by real time RT-PCR. Over-
expression of miR-21 was observed in MIAPaCa-2 tumors whereas
we found a significant reduction in the expression of miR-21 in
tumors treated with either CDF alone or in combination with CDF
and gemcitabine (Figure 7D). We further determined the expression
levels of miRNA-200b and miR-200c in tumor tissues which are
known regulators of EMT and found to be significantly low in
Figure 6. CDF treatment decreased the expression of CD44 and EpCAM, the known markers of CSCs. Expression in pancreatospheres of
AsPC-1 and AsPC-1-GTR cells was assessed by confocal microscopy (Magnification X250).
doi:10.1371/journal.pone.0017850.g006
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treatment with or without gemcitabine combination showed
increased expression of both miR-200b, and miR-200c, but the
effect with curcumin or its combination was minimal, suggesting the
superiority of CDF in suppressing the expression of miR-21,
resulting in the re-expression of PTEN, and re-expression of miR-
200 which could be responsible for the reversal of EMT phenotype
in cells treated with CDF. Overall, these results suggest that the
phenotypic characteristics of MIAPaCa-2 tumors are consistent
with enriched population of CSCs and EMT characteristics, and
these drug resistant cells could be killed either by CDF alone or in
combination with gemcitabine.
Pancreatospheres enhanced tumor growth in vivo
Under traditional experimental conditions, we normally inject
one million cells for assessing tumor growth; however, for
Figure 7. CDF exhibited anti-tumor activity in MIAPaCa-2 cells induced tumors in a xenograft mouse model, which was consistent
with inhibition of NF-kB DNA binding, COX-2, miR-21, and caused re-expression of miR200 in tumor remnants. Anti-tumor activity and
changes in tumor weight from each group of animals (A). The arrow indicates starting day of the treatment. NF-kB DNA binding activity of tumor
tissues; and NF-kB competition control study with unlabeled NF-kB oligonucleotide (B). Western blots analysis of COX-2, PTEN and b-actin expression
in tumor remnants (C); miR-21, miR-200b and miR-200c expression in tumor remnants as measured by real-time RT-PCR (D). P values were calculated
by the paired t test.
doi:10.1371/journal.pone.0017850.g007
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spheres, we injected only 5,000 cells in mice as a proof-of-concept
study. The tumor weight was remarkably increased as the days
progressed (Figure 8A). The level of miR-21 was increased
between tumors implanted with one million of parental cells
compared to pancreatospheres (Figure 8B). The animal was
euthanized after 30 days because of tumor burden, and gross
tumors are shown in Figure 8C indicating larger tumors as well as
loco-regional lymph node metastasis whereas tumors derived from
parental cells did not show any metastasis over a period of 30 days.
The tumor-derived cells showed significant inhibition of pancrea-
tospheres when treated with CDF (Figure 8D). Overall, these
results suggest that CSCs (pancreatospheres) can be grown in mice
and CDF could be useful for the killing of these drug resistant cells
(Figure. 8).
Discussion
In this study, we have demonstrated that a synthetic analogue of
curcumin, CDF, is significantly more effective compared to
curcumin in the killing of gemcitabine-resistant pancreatic cancer
(PC) cells that consists high proportion of cells with cancer stem
cells (CSCs) or cancer stem-like cells characteristics. The inhibition
of cell growth could in part be due to better cellular uptake,
retention and reduced metabolic inactivation of CDF by PC cells,
which is consistent with our published findings on cellular and
animal pharmacokinetics data [10,11]. Our previous reports
indicate that CDF inhibits NF-kB and COX-2 activity in PC
cells in vitro [12]. Here we confirm these observations in vivo using a
mouse xenograft model. Thus, the killing of gemcitabine-resistant
PC cells by CDF is associated with inactivation of NF-kB and
COX-2 signaling pathway which is very important because these
Figure 8. Tumor growth pattern of pancreatospheres derived from MIAPaCa-2 cells. (A). 5,000 pancreatospheres were inoculated in mice
using 1:1 matrigel, progressive tumor growth over a period of 30 days. Moderate increase in the expression of miR-21 as measured by real-time RT-
PCR was observed in tumors derived from pancreatospheres compared to tumors derived from parental cells by injecting one million cells and tumor
was assessed over the same period of time (B). Photographs showing tumor growth, arrow points to tumor and asterisk (*) refers to loco-regional
lymph node metastasis whereas we did not find any metastasis when one million parental cells were injected (C). Tumor cells harvested from the
tumors derived from pancreatospheres were treated with CDF showed significant inhibition in the formation of pancreatospheres (D).
doi:10.1371/journal.pone.0017850.g008
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to chemotherapeutic agents [16–18].
CSCs comprises only a very small proportion of cells in a tumor
mass and posses the ability to self-renew and give rise to
differentiated tumor cells [3–5,19]. The CSC theory has
fundamental clinical implications especially because CSC has
been identified in many malignant tumor tissues including
pancreatic cancers and considered to be highly resistant to
chemo-radiation therapy than differentiated daughter cells [3–
5,20]; however, CSCs isolated from human tumors are usually
insufficient for further mechanistic studies. The existence of CSCs
provides an explanation for the clinical observation that tumor
regression alone may not correlate with patient survival [21]
because of tumor recurrence, which is in part due to the presence
of CSCs. Therefore, targeting self-renewal pathways and the
killing of CSCs might provide more specific approach for
eliminating cells that are the root cause of tumor recurrence. A
potential challenge in this regard is the development of therapies
that selectively affect CSCs while sparing normal stem cells that
may rely on similar mechanisms for self-renewal. In this study, we
have demonstrated that CDF not only inhibit cell growth of PC
cells, but also inhibit CSC self-renewal capacity as assessed by
sphere formation (pancreatospheres) assays. Therefore, CDF could
have a greater potential to inhibit cancer growth as documented
by our xenograft mouse model of gemcitabine resistant PC cells,
which appears to be mediated via inhibition of CSC self-renewal
capacity.
Emerging evidence suggests the role of microRNA (miRNA) in
many biological processes [22–25]. Among many miRNAs, miR-
21, commonly considered as an oncogene, is over-expressed in
many solid tumors including PC and has been reported to be
associated with tumor progression, poor survival and drug
resistance [13,14,26,27]. In our previous report, we have
demonstrated that the expression of miR-21 is up-regulated in
gemcitabine-resistant PC cells and that its expression can be
significantly down-regulated by CDF treatment in vitro [12]. The
increased expression of miR-21 is known to be associated with
inactivation of PTEN, a know tumor suppressor gene, resulting in
activation of PI3K/Akt/mTOR signaling pathway, leading to
aggressive tumor growth [15,28]. In this study, we confirmed that
CDF treatment could results in the down-regulation of miR-21,
resulting in the up-regulation of PTEN in vivo, suggesting that the
anti-tumor activity of CDF is associated with up-regulation of
PTEN resulting from the inactivation of miR-21 expression.
In contrast to miR-21, miR-200 family is known as tumor
suppressor and they are usually down-regulated in some tumors
including PC and the loss of expression of miR-200 family
contribute to the acquisition of EMT phenotype and drug
resistance. Down-regulation of miR-200 by siRNA technique
has been shown to be associated with EMT phenotype while re-
expression of miR-200 can result in the reversal of EMT
phenotype [29,30]. In our previous publication [12], we
demonstrated that CDF treatment could re-express miR-200 in
PC cells. Here we showed, for the first time, that CDF can up-
regulate miR-200b and miR-200c in tumor remnants in vivo,
consistent with significantly greater inhibition of tumor growth in
the xenograft mouse model when CDF was used in combination
with gemcitabine. These results suggest that the anti-tumor activity
of CDF is mediated via re-expression of miR-200 which may
potentially results in the reversal of EMT phenotype and could
also lead to overcome drug resistance in PC.
In conclusion, CDF showed much more pronounced growth
inhibitory effect, inhibited CSC self-renewal consistent with
inactivation of CSC biomarkers (CD44 and EpCAM) in PC cells
especially in gemcitabine-resistant PC cells compared to curcumin.
In xenograft mouse model of human PC tumors induced by
MIAPaCa-2 cells, CDF exhibits anti-tumor activity by regulating
COX-2, PTEN, miR-21, miR-200, and NF-kB in vivo. These
results strongly suggest that CDF could be a novel agent for the
treatment of PC in general but gemcitabine-resistant PC in
particular by attenuating the behavior of CSCs.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. Any
animal found unhealthy or sick were promptly euthanized. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of Wayne State University institutional Users Animal
Care Committee (Permit Number: A-10-03-08).
Cell Culture, Drugs and Reagents
Human pancreatic cancer cell lines AsPC-1, and MIAPaCa-2
were purchased from ATCC (Manassas, VA). These two cell lines
AsPC-1 and MIAPaCa-2 were exposed to 200 nmol/L of
gemcitabine and 5 mmol/L of tarceva (erlotinib) every other week
for about 6 months to create gemcitabine and tarceva resistant
(GTR) cell lines, named as AsPC-1-GTR and MIAPaCa-2-GTR,
respectively. As a result, AsPC-1, AsPC-1-GTR, MIAPaCa-2, and
MIAPaCa-2-GTR were chosen for this study based on their
differential sensitivities to gemcitabine. All the cell lines have been
authenticated (Applied Genomics Technology Center at Wayne
State University) on March 13, 2009 and these authenticated cells
were frozen for subsequent use. The method used for testing was
short tandem repeat profiling using the PowerPlex 16 System from
Promega. Gemcitabine and curcumin were purchased from Eli
Lilly (Indianapolis, IN) and Sigma-Aldrich (St. Louis, MO),
respectively. CDF was synthesized as described in our earlier
publication [10,11]. Gemcitabine was dissolved in water, whereas
CDF and curcumin were dissolved in DMSO with a final
concentration of 0.1% DMSO in medium.
Antibodies
Antibodies against ABCG2, and PTEN were purchased from
Santa Cruz (Santa Cruz, CA). Antibody to COX-2 and b-actin
was acquired from Cayman Chemicals (Ann Arbor, MI), and
Sigma Chemicals (St. Louis, MO).
Clonogenic assay
Clonogenic assay was conducted to examine the effect of drugs
on cell growth in PC cells, as described previously [12]. 5610
4
cells were plated in a six-well plate. After 72h of exposure to 20
nmol/L of gemcitabine, 4 mmol/L of CDF or curcumin, the cells
were trypsinized, and 1,000 single viable cells were plated in 100-
mm Petri dishes. The cells were then incubated for 10 to 12 days
at 37uC in a 5% CO2/5% O2/90% N2 incubator. Colonies were
stained with 2% crystal violet and counted.
Invasion assay
The invasive activity of cells was tested by using BD BioCoat
Tumor Invasion Assay System (BD Biosciences, Bedford, MA)
according to the manufacturer’s protocol as described previously
[31]. Briefly 5610
4 cells were seeded with serum free medium
supplemented with curcumin or CDF into the upper chamber and
bottom wells were filled with complete medium in the system. The,
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590 nm and were photographed.
Cell survival assay
MTT assay was conducted using AsPC-1, AsPC-1-GTR,
MIAPaCa-2, and MIAPaCa-2-GTR as described previously [12]
after 72 h of treatment. Combination index and Isobologram for
combination treatment were also calculated and plotted using
CalcuSyn software (Biosoft, Cambridge, United Kingdom) to
determine synergy based on the method of Chou and Talalay [32].
Sphere formation/disintegration assay
Single cell suspensions of cells were plated on ultra low adherent
wells of 6-well plate at 1,000 cells/well in sphere formation
medium [33]. After 7 days, the spheres termed as ‘‘pancreato-
spheres’’ were collected by centrifugation and counted [33]. For
sphere disintegration assay, 1,000 cells/well were incubated for 10
days, following 5 days of drug treatment, which examined the
effect of drug treatment on disintegration of pancreatospheres as
described previously [33]. The pancreatospheres were collected by
centrifugation and counted under a microscope.
Confocal microscopy
Single cell suspensions of AsPC-1 and AsPC-1-GTR cells were
plated using ultra low adherent wells of 6-well plate at 3,000 cells/
well in sphere formation medium. After 7 days of treatment, the
pancreatospheres were collected by centrifugation, washed with
1xPBS, and fixed with 3.7% parformaldehyde. CD44 and
EpCAM antibodies were used for immunostaining assay, as
described previously [29]. The CD44 or EpCAM-labeled
pancreatospheres were photographed by confocal microscopy
(Leica TCS SP5) using software LAS AF 1.2.0 Build 4316.
Protein extraction and Western blot analysis
Proteins were extracted from all four cell lines and also from
animal tumor tissues as described previously [12]. Relative level of
ABCG2 was evaluated for all four cell lines. The effects on COX-
2, PTEN and b-actin expression were evaluated on tumor tissues
by Western blot analysis. as described previously [12].
Animal Experiments
The animal protocol was approved by the Animal Investigation
Committee, Wayne State University, Detroit, MI. Female CB17
SCID mice 4 wks old were purchased from Taconic Farms
(Germantown, NY) and fed Lab Diet 5021 (Purina Mills, Inc.,
Richmond, IN). Small fragments of the MIAPaCa-2 xenograft
were implanted subcutaneously and bilaterally into mice for the
drug-efficacy trials. Once the mice developed palpable tumors,
they were randomly selected into the following treatment groups
(n = 5/group): (1) untreated control; (2) CDF (5 mg/mouse/day),
intragastric once daily for 12 days; (3) curcumin (5 mg/mouse/
day), intragastric once daily for 12 days; (4) gemcitabine (1 mg/
mouse/day), intravenous every third day for a total of three doses;
(5) CDF and gemcitabine using the doses indicated above; (6)
curcumin and gemcitabine using the doses as indicated above.
Tumor measurements and changes in weight were performed and
tissue was stored at 270uC for RNA and protein extraction.
Electrophoretic Mobility Shift Assay (EMSA) assay for
assessing the DNA binding activity of NF- kB
Nuclear proteins were prepared from tumors tissue using a
Dounce homogenizer with 400 ml of ice cold lysis buffer extracted
as described earlier [34]. EMSA was performed using the Odyssey
Infrared Imaging System with NF-kB IRDye labeled oligonucle-
otide from LI-COR, Inc. (Lincoln, NE). Ten mg of the nuclear
protein extract was used as described earlier [34]. The NF-kB
competition control study was conducted using unlabeled NF-kB
consensus oligonucleotide. The samples were loaded and run at
30 mA for 1 hour. The gel was scanned using Odyssey Infrared
Imaging System (LI-COR, Inc.).
TaqMan miRNA Real-Time Reverse Transcriptase-
Polymerase Chain Reaction (RT-PCR)
To determine the expression of miRNAs (miRNA-200b, miR-
200c, and miR-21) in MIAPaCa-2 tumors, we used TaqMan
MicroRNA Assay kit (Applied Biosystems) following manufactur-
er’s protocol. 5 ng of total RNA was reverse transcribed and real-
time PCR reactions were carried as described earlier [30], using
Smart Cycler II (Cepheid). Data were analyzed using Ct method
and were normalized by RNU6B expression.
Growth of CSC in xenograft model
5,000 pancreatospheres were isolated and implanted in mice
with 1:1 matrigel. The growth rate was observed for a period of 30
days. RNA was extracted from the tumor tissue for subsequent
molecular assays as presented under figure legend.
Statistical Analysis
Comparisons of treatment outcome were tested for statistical
difference by the paired t tests. Statistical significance was assumed
at a P value of ,0.05.
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